AVSEHQLLHDKGKSIQDLRRRFFLHHLI-{Aib}-EIHTAYRFGG
Modify Date: 2025-08-25 18:43:13
AVSEHQLLHDKGKSIQDLRRRFFLHHLI-{Aib}-EIHTAYRFGG structure
|
Common Name | AVSEHQLLHDKGKSIQDLRRRFFLHHLI-{Aib}-EIHTAYRFGG | ||
|---|---|---|---|---|
| CAS Number | 2640019-27-6 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of AVSEHQLLHDKGKSIQDLRRRFFLHHLI-{Aib}-EIHTAYRFGGAVSEHQLLHDKGKSIQDLRRRFFLHHLI-{Aib}-EIHTAYRFGG promotes bone-ossification. AVSEHQLLHDKGKSIQDLRRRFFLHHLI-{Aib}-EIHTAYRFGG can be used in the research of diseases or disorders related to osteogenic defects or bone mineral density (BMD) decreasing, such as osteoporosis[1]. |
| Name | AVSEHQLLHDKGKSIQDLRRRFFLHHLI-{Aib}-EIHTAYRFGG |
|---|
| Description | AVSEHQLLHDKGKSIQDLRRRFFLHHLI-{Aib}-EIHTAYRFGG promotes bone-ossification. AVSEHQLLHDKGKSIQDLRRRFFLHHLI-{Aib}-EIHTAYRFGG can be used in the research of diseases or disorders related to osteogenic defects or bone mineral density (BMD) decreasing, such as osteoporosis[1]. |
|---|---|
| Related Catalog | |
| In Vivo | AVSEHQLLHDKGKSIQDLRRRFFLHHLI-{Aib}-EIHTAYRFGG (2.5 and 5 μg/kg, s.c.) promotes ossification in Ovariectomy (OVX)-induced osteoporosis rats[1]. Animal Model: Ovariectomy (OVX)-induced osteoporosis rats[1] Dosage: 2.5 μg/kg, 5 μg/kg Administration: Subcutaneous injection (s.c.) Result: Increased bone mineral density in thigh bone and lumbar vertebra. |
| References |
[1]. Fu Guoqin, et al. Active polypeptide compound. Patent. WO2021068550. |
| No Any Chemical & Physical Properties |